**Core Concept**
Diethylstilbestrol (DES) is a synthetic estrogen that was prescribed to pregnant women between 1940 and 1971. Intrauterine exposure to DES has been linked to various reproductive tract abnormalities and cancers.

**Why the Correct Answer is Right**
DES is a potent estrogen agonist that disrupts normal embryonic development. In utero exposure to DES has been associated with an increased risk of clear cell adenocarcinoma (CCA) of the vagina and cervix. This is due to the abnormal differentiation and proliferation of epithelial cells in the vagina and cervix, leading to the development of CCA. The exact mechanism involves the activation of estrogen receptors in these cells, which promotes oncogenic changes.

**Why Each Wrong Option is Incorrect**
**Option A:** Squamous cell carcinoma of cervix is not directly associated with intrauterine DES exposure. While DES exposure may increase the risk of cervical abnormalities, squamous cell carcinoma is not the primary concern.
**Option B:** Adenocarcinoma of the endometrium is a different type of cancer that is not directly linked to intrauterine DES exposure. Endometrial cancer is more commonly associated with factors like obesity, unopposed estrogen exposure, and genetic predisposition.
**Option D:** Sarcoma of the uterus is a rare type of cancer that is not associated with intrauterine DES exposure. Sarcomas are typically aggressive tumors that arise from connective tissue, and their development is not linked to estrogen exposure.

**Clinical Pearl / High-Yield Fact**
DES exposure in utero is a classic example of a teratogenic effect, where a substance disrupts normal embryonic development and increases the risk of specific birth defects or cancers. This highlights the importance of careful medication use during pregnancy and the need for ongoing surveillance of exposed individuals.

**✓ Correct Answer: C. Clear cell adenocarcinoma of vagina**